Latest Breaking News On - Next generation tyrosine kinase inhibitor - Page 1 : comparemela.com

Bristol Myers Squibb today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Augtyrotm (repotrectinib) for the treatment of adult and pediatric patients 12 years of age and older with solid tumors that.

Bristol myers squibbNick botwoodAlexander drilonSusan spinosaDrug administration approves augtyrotmNational cancer instituteBristol myers squibb companyExchange commissionProduct serviceEuropean society for medical oncologyDrug administrationNext generation tyrosine kinase inhibitorPositive locally advancedMetastatic solidMyers squibbEarly drug development service